Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021

Publication

Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021

Journal Paper/Review - Mar 12, 2021

Fankhauser Christian Daniel, Tandstad Torgrim, Nicolai Nicola, Nicol David, Leão Ricardo, Muilwijk Tim, Janisch Florian, Mayor de Castro Javier, Gremmels Hendrik, Fizazi Karim, Fischer Stefanie, Boormans Joost L, Bokemeyer Carsten, Algaba Ferran, Albers Peter, Oldenburg Jan, Pilar Laguna M

Citation

Fankhauser C, Tandstad T, Nicolai N, Nicol D, Leão R, Muilwijk T, Janisch F, Mayor de Castro J, Gremmels H, Fizazi K, Fischer S, Boormans J, Bokemeyer C, Algaba F, Albers P, Oldenburg J, Pilar Laguna M. Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021. Eur Urol 2021; 80:4-6.

Type

Journal Paper/Review (English)

Journal

Eur Urol 2021; 80

Publication Date

Mar 12, 2021

Issn Electronic

1873-7560

Pages

4-6

Brief description/objective

Men with metastatic germ cell tumors undergoing chemotherapy are at high risk of venous thromboembolic events and low risk of bleeding. A central venous-access device should be avoided whenever possible. Thromboprophylaxis may be prescribed after balancing the risks and benefits for each individual patient.